Baruch Halpert
Président chez Terragenic International Ltd.
Profil
Baruch Halpert is currently the Executive Chairman at Terragenic International Ltd.
He previously worked as a Director at Enlivex Therapeutics Ltd.
and holds a graduate degree from The University of Reading.
Postes actifs de Baruch Halpert
| Sociétés | Poste | Début |
|---|---|---|
| Terragenic International Ltd. | Président | 01/01/2018 |
Anciens postes connus de Baruch Halpert
| Sociétés | Poste | Fin |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Directeur/Membre du Conseil | - |
Enlivex Therapeutics Ltd. /Old/
 Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Directeur/Membre du Conseil | - |
Formation de Baruch Halpert
| The University of Reading | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
| Terragenic International Ltd. |
